The primary objective of this study is to evaluate the safety and tolerability of the study drug RGLS829 in adults with autosomal dominant polycystic kidney disease (ADPKD). The study also aims to assess the impact of RGLS8429 on ADPKD biomarkers, height-adjusted total kidney volume (htTKV), and renal function in those living with ADPKD.